Calcimedica reports first quarter 2025 financial results and provides clinical & corporate updates

Enrollment ongoing in phase 2 kourage trial of auxora™ in acute kidney injury (aki) and respiratory failure; data expected around the end of 2025 presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with aki in the phase 2 cardea trial of auxora in severe covid-19 pneumonia, which showed a 62.7% relative reduction in mortality for auxora versus  placebo cash position expected to fund operations into mid-2026 la jolla, calif. , may 14, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended march 31, 2025 and provided clinical and corporate updates.
CALC Ratings Summary
CALC Quant Ranking